Results 91 to 100 of about 1,033,768 (122)
What general practitioners need to know about patent foramen ovale [PDF]
, 2014 A patent foramen ovale (PFO) consists of a hole between the right and left atriums of the heart that did not close the way it should after birth. Twenty five percent of the population have a PFO, but this usually does not cause problems, because the ...
Saliba, Mario
core
, 2019 For centuries, people have talked of a powerful bodily disorder called migraine, which currently affects about a billion people around the world. Yet until now, the rich history of this condition has barely been told. In Migraine, award-winning historian
Foxhall, Katherine
core
[Diagnosis and therapy of the resistant migraines].
Medicinski pregled, 2003 openaire +1 more source
Positive airway pressure (PAP) as a remedy for treatment-resistant migraine – A case report
Lung IndiaBavneet Kaur +4 more
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Migraine and Treatment-Resistant Depression
Progress in Brain Research, 2023Migraine and major depressive disorders (MDD) or treatment resistant depression (TRD) represent a significant global burden and are often comorbid, further complicating diagnosis and treatment. Epidemiological studies have demonstrated a bidirectional relationship between migraine and MDD/TRD, with patients suffering from one disorder exhibiting a ...
Shih-Pin Chen
exaly +3 more sources
Advances in Pharmacotherapy for the Prophylactic Treatment of Resistant and Refractory Migraine
Expert Opinion on Pharmacotherapy, 2022Refractory migraine is associated with low quality of life and great socioeconomic burden. Despite high need for effective, tolerable preventive therapies, there has been little research on potential therapeutic options. Monoclonal antibodies (mAbs) against Calcitonin Gene-Related Peptide (CGRP) are the first preventive therapeutic approach for ...
Bianca Raffaelli +2 more
exaly +3 more sources
Current Neurology and Neuroscience Reports, 2022
Migraine is one of the top reasons for consulting a pediatric neurologist. Although the majority of children and adolescents who receive evidence-based first-line interventions for migraine will improve substantially, a subset of patients develop resistant or refractory migraine.In this review, we summarize the level of evidence for a variety of acute ...
Michelle A Clementi, Serena Orr
exaly +3 more sources
Migraine is one of the top reasons for consulting a pediatric neurologist. Although the majority of children and adolescents who receive evidence-based first-line interventions for migraine will improve substantially, a subset of patients develop resistant or refractory migraine.In this review, we summarize the level of evidence for a variety of acute ...
Michelle A Clementi, Serena Orr
exaly +3 more sources
Cephalalgia, 2003
The aim was to explore whether combining a β-blocker and sodium valproate could lead to an advantage in efficacy in patients with migraine previously resistant to the two medications in monotherapy. Fifty-two patients (43 women) with a history of episodic migraine with or without aura, and previously unresponsive to β-blockers and sodium valproate in ...
Julio Pascual, J M Laínez
exaly +3 more sources
The aim was to explore whether combining a β-blocker and sodium valproate could lead to an advantage in efficacy in patients with migraine previously resistant to the two medications in monotherapy. Fifty-two patients (43 women) with a history of episodic migraine with or without aura, and previously unresponsive to β-blockers and sodium valproate in ...
Julio Pascual, J M Laínez
exaly +3 more sources
A New Option for Patients With Treatment-Resistant Migraine
Lancet Neurology, The, 2022Raffaele Ornello, Simona Sacco
exaly +4 more sources
Oral dihydroergotamine for therapy-resistant migraine attacks in children
Pediatric Neurology, 1997Twelve children with migraine symptoms that did not respond to conventional analgesics completed a double-blind, placebo-controlled, cross-over study of two doses of oral dihydroergotamine (DHE) for acute treatment. The primary endpoint was reduction of headache by > or = 2 grades on a 5-grade scale at 2 hours.
M L, Hämäläinen +2 more
openaire +2 more sources